COMMUNIQUÉS West-GlobeNewswire

NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
21/04/2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company [...]
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
21/04/2026
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
21/04/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established [...]
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
21/04/2026
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application [...]
Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors
21/04/2026
LOS ANGELES, April 21, 2026 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical-stage biopharmaceutical company developing first-in-class therapies for cancer, autoimmune, and neuroimmune diseases, today [...]
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
21/04/2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy FLORHAM PARK, N.J., April 21, 2026 (GLOBE [...]
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
21/04/2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present [...]
AuX Labs Secures $4M to Commercialize Precision Fermentation Cheese Platform
21/04/2026
Funding will accelerate the launch of a scalable, precision-fermented dairy protein technology that performs like traditional cheese TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- AuX Labs, a food technology company using [...]
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
21/04/2026
Expansion Adds to Growing Global Trial Footprint Patient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), [...]
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
21/04/2026
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed [...]
Brain Cancer Canada Marks Brain Cancer Awareness Month in May with National Landmark Lightings, Community Events, New Research Investments, and a Call to Action
21/04/2026
Awareness events Research grant awards Gala for Brain Cancer Research with Catherine Wreford and Dr. Cynthia Hawkins TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- Brain Cancer Canada (BCC), the only national charity [...]
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
21/04/2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment
21/04/2026
Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access 79% secondary patency at 12 months in complex patient populations [...]
Le Gala de la Fondation de l’Hôpital de Lachine recueille 322 115 $ pour transformer les soins de santé dans l’Ouest-de-l’Île
21/04/2026
DORVAL, Québec, 21 avr. 2026 (GLOBE NEWSWIRE) -- Le Gala de la Fondation de l’Hôpital de Lachine a permis de recueillir 322 115 $. Cette somme servira à soutenir la campagne Osez rêver : Hôpital de Lachine , un [...]
Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
21/04/2026
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla [...]
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
21/04/2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical [...]
Eclipse Energy and Wood to Scale Hydrogen Production from End-of-Life Oil Fields
21/04/2026
Strategic collaboration positions Wood as a preferred engineering partner as Eclipse moves its reservoir-to-hydrogen technology toward global project development HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- As demand [...]
Celularity Announces Closing of Transaction with NexGel
21/04/2026
FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of its previously [...]
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been [...]

Pages